The function of the E3 ligase RNF38 is still unknown in gastric cancer. Here, we found that RNF38 is upregulated in gastric cancer, and it is associated with the overall survival of gastric cancer patients. Further studies showed that RNF38 interacts with the nonreceptor tyrosine phosphatase SH2-containing protein tyrosine phosphatase 1 (SHP-1) and induces the polyubiquitination of SHP-1, which leads to destabilization of SHP-1 and promotion of STAT3 signaling in gastric cancer cells. In addition, overexpression or knockdown of RNF38 induces or suppresses gastric cancer cell growth in vitro, respectively, and silencing RNF38 delays tumor growth in vivo. These findings demonstrate that RNF38 is functional in gastric cancer and promotes STAT3 signaling by destabilizing SHP-1; thus, RNF38 could be a novel target for gastric cancer therapy.
RING finger protein 38 (RNF38) belongs to the largest RING ubiquitin ligase family, and it contains a RING-H2 motif and a coiled-coil motif at its carboxyterminus [1] . The RING-type zinc finger motif is a zinc-binding domain found in the RING ubiquitin ligase family proteins, which plays important roles in many cellular processes including protein degradation, signal transduction, cell growth and oncogenesis [2] . Dysregulation of RNF38 is associated with a variety of diseases, including tumors. In nonsmall cell lung cancer (NSCLC), RNF38 was elevated and this promoted the proliferation and metastatic capacity of NSCLC cells [3] . Furthermore, RNF38 has been reported to be a binding partner of p53 and induced the polyubiquitination of p53 in vitro and in vivo [4] . And overexpression of RNF38 resulted in relocalization of p53 to discrete foci associated with PML nuclear bodies [4] . Considering the extensive involvement of RNF38 in regulating p53 function, there is an urgent demand to identify the function and molecular mechanisms of RNF38 in gastric cancer.
SH2-containing protein tyrosine phosphatase 1 (SHP-1) is a nonreceptor protein tyrosine phosphatase, and inhibits various tyrosine kinases by dephosphorylation [5, 6] .
SHP-1 can act as a negative regulator of STAT3 signaling and it serves as a tumor suppressor in many cancers, including gastric cancer, lung cancer, breast cancer, liver cancer and so on [7] . Recent studies showed that SHP-1 could be ubiquitinated and degraded into the ubiquitinproteasome pathway [8] . However, the ubiquitination mechanism of SHP-1 in gastric cancer was still unknown.
In this study, we investigated the altered expression of RNF38 and the mechanism of RNF38 as an E3 ligase. We found that RNF38 was highly expressed in gastric cancer and predicted a poor prognosis of gastric cancer patients. Moreover, as an E3 ligase, RNF38 mediated the polyubiquitination of SHP-1 and induced its degradation through the ubiquitin-proteasome pathway. Overexpression or knockdown of RNF38 promoted or suppressed, respectively, the phosphorylation of STAT3 in gastric cancer cells and regulated the cell growth of gastric cancer cells. These results indicated that RNF38 may be a novel biomarker of gastric carcinogenesis, and targeting RNF38/ SHP-1/STAT3 axis could be a potential strategy for gastric cancer therapy.
Materials and methods

Cells, tissues and chemicals
Gastric cancer cell lines AGS, NCI-N87, MGC80-3 and SNU-1 cell lines, and human normal gastric mucosal cell line GES-1 were purchased from Shanghai Cell Institute of Chinese Academy of Sciences (Shanghai, China). HEK293 was purchased from American Type Culture Collection (Manassas, VA, USA). All gastic cancer cell lines, human normal gastric mucosal cell line and HEK293 were maintained in Dulbecco's high glucose modified Eagle's medium with 10% fetal bovine serum, 100 lgÁmL À1 of penicillin and 100 unitsÁmL À1 of streptomycin. The primary gastric cancer tissues and paracancerous normal tissues were collected from the First Affiliated Hospital of Soochow University. The collection and use of human tissues for this study were approved by the Institutional Review Board of Soochow university. Cycloheximide (CHX) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted using Trizol Ò Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions as described previously [9] . cDNA was synthesized from equal quantities of total RNA by using the EasyScript First-Strand cDNA Synthesis SuperMix (TransGen Biotechnology, Nanjing, China) according to the manufacturer's instructions. To determine the mRNA levels of 
Immunoblotting analysis
The primary gastric cancer tissues' lysates and indicated whole cell lysates were prepared for immunoblotting as described previously [10] . 
Immunohistochemistry staining
Gastric cancer tissues and individual normal tissues were fixed in 10% formalin before being embedded in paraffin. The tissues were cut into 6-micron thickness with a microtome, and the slides were deparaffinized and rehydrated before antigen retrieval. All slides were then subjected to blocking in 10% normal horse serum for 10 min, followed by incubating with the primary antibodies RNF38 (Santa Cruz Biotechnology) or SHP-1 (Cell Signaling Technology) overnight at 4°C. Subsequently, a biotin-conjugated secondary antibody diluted with Tris-based buffer (TBS) containing 10% serum and 1% BSA was applied to incubate for 10 min. Then, the slides were rinsed with cold TBS, and incubated with Streptavidin-peroxidase for 10 min before being stained with 3,3 0 -diaminobenzidine (Invitrogen). Finally, the slides were stained with hematoxylin and eosin before being mounted for microscopy analysis.
Plasmids construction and gene transfection
The human RNF38, SHP-1 and ubiquitin genes were generated and cloned into pcDNA3.1 vector with a Myc, Flag or HA tag as previously described [11] . A STAT3 luciferase construct (STAT3-Luc) driven by specific STAT3 response elements was purchased from Beyotime Biotechnology, Inc. Plasmids were transiently transfected into HEK293 or SNU-1 cells by Lipofectamine Ò 2000 (Invitrogen) according to the manufacturer's instruction.
Coimmunoprecipitation (CoIP)
Whole cell lysates were prepared for CoIP as described previously [9] . In specific, whole cell lysates were incubated with a specific primary antibody overnight at 4°C, followed by incubating with protein A/G-Sepharose beads (Santa Cruz Biotechnology) for 3 h. The captured proteins were then subjected to immunoblotting analysis against specific antibodies.
Preparation of shRNA Lentivirus
The lentivirus-delivered shRNAs against RNF38 (shRNF38) and the negative control (shNC) were purchased from Santa
Cruz Biotechnology, Inc. (Catalog #, sc-92932). The viral particles were prepared with a standard protocol as manufacturer's instructions as described previously [9] .
Cycloheximide chase assay
To evaluate whether RNF38 regulated the stability of SHP-1 protein, SNU-1 cells were transfected with vector or RNF38 plasmids by Lipofectamine Ò 2000 (Invitrogen) for 24 h. Then, cells were treated with 50 lgÁmL À1 CHX for a specific time period before being prepared for immunoblotting as described previously [12] .
Cell growth and viability 
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Representative gastric cancer tissues and individual normal tissues were prepared for immunohistochemical staining using anti-RNF38 and SHP-1 antibodies. (E) Whole cell lysates of four gastric cancer cell lines (AGS, NCI-N87, MGC80-3 and SNU-1) and one normal gastric mucosal cell line were extracted for immunoblotting against RNF38 and SHP-1. GAPDH was used as a loading control. *P < 0.05, **P < 0.01.
manufacturer's instructions (Biotool, Houston, TX, USA) as described previously [13] .
Dual-luciferase reporter assays
SNU-1 cells were transfected with pSTAT3-Luc, Myc-RNF38 or empty vector plasmids along with the internal control Renilla by Lipofectamine Ò 2000 (Invitrogen)
according to the manufacturer's instruction. Thirty-six hours later, cells were prepared for luciferase assays using Dual-Luciferase Ò Reporter Assay System (Promega, Madison, WI, USA) as described previously [14] .
Xenograft studies
The human gastric cancer cells SNU-1 infected with shRNF38 or scramble lentivirus were injected subcutaneously in the right flanks of nude mice (Shanghai Slac Laboratory Animal Co. Ltd., Shanghai, China) with a density of 8 million cells/site/mouse individually. When tumors were palpable, tumor sizes were measured every other day. At the end of the experiment, tumors were excised for further evaluation. This animal study was approved by the Review Board of Animal Care and Use of Soochow University.
Statistical analysis
The student's t test was used for comparing two groups in the studies. All statistical tests were two-sided, and a P value < 0.05 was considered statistically significant.
Results
RNF38 is upregulated in gastric cancer along with SHP-1 downregulation
To evaluate the expression levels of RNF38 in gastric cancer, the TCGA database from GEPIA website was first used for analysis. As shown in Fig. 1A , RNF38 was obviously upregulated in tumor tissues from gastric cancer. To further confirm this result, 20 pairs of adjacent normal tissues and tumor tissues from gastric cancer patients were collected, and qRT-PCR indicated that the mRNA level of RNF38 was significantly higher in tumor tissues than the adjacent normal tissues (Fig. 1B) . Kaplan-Meier plotter also indicated that RNF38 was a negative index for patient survival of gastric cancer (Fig. 1C) . In addition, the protein level of RNF38 was also upregulated in representative tumor tissues along with the downregulation of SHP-1 protein (Fig. 1D) . RNF38 was also upregulated and SHP-1 was downregulated in gastric cancer cell lines compared with normal gastric mucosal cell line (Fig. 1E ).
RNF38 interacts with SHP-1 and induces the polyubiquitination of SHP1
The results above showed that RNF38 was upregulated in gastric cancer, but SHP-1 was downregulated. As RNF38 is an E3 ligase, we then assessed whether RNF38 interacted with SHP-1 and induced the degradation of SHP-1 through the ubiquitination-proteasome pathway. Firstly, to evaluate whether RNF38 interacted with SHP-1, Myc-RNF38 or Flag-SHP-1 plasmids were transfected into HEK293 cells. As shown in Fig. 2A ,B, the reciprocal coimmunoprecipitation assay showed that RNF38 interacted with SHP-1. And the whole cell lysates were also prepared for immunoblotting, and the results showed that RNF38 downregulated the expression level of SHP-1 ( Fig. 2A,B) . Subsequently, the immunoprecipitation assay showed that SHP-1 itself was polyubiquitinated and RNF38 could significantly enhanced the polyubiquitination of SHP-1 protein (Fig. 2C) . Figure 2D also revealed that RNF38 downregulated SHP-1. 
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RNF38 decreases the stability of SHP-1 protein
The above studies indicated that RNF38 interacted with SHP-1 and enhanced its polyubiquitination. Because polyubiquitination is a key factor in protein degradation, we then assessed whether RNF38 regulated the protein stability of SHP-1. To this end, Myc-RNF38 and Flag-SHP-1 plasmids were cotransfected into HEK293 cells, and the results showed that RNF38 downregulated the exogenous protein levels of SHP-1 in a concentration-dependent manner (Fig. 3A) . To further confirm this result, SNU-1 cells were transfected with increasing concentrations of Myc-RNF38 plasmids, and the immunoblotting assay showed that RNF38 decreased the endogenous protein levels of SHP-1, but not the mRNA level (Fig. 3B,C) . In contrast, knockdown of RNF38 enhanced the protein levels of SHP1, but not the mRNA levels (Fig. 3D,E) .
Moreover, the proteasome inhibitor MG132 could significantly partially reverse RNF38-mediated SHP-1 degradation (Fig. 3F,G) . The CHX chase assay also revealed that RNF38 shortened the half-life of SHP-1 protein (Fig. 3H,I ).
RNF38 mediates STAT3 signaling and promotes gastric cancer cell growth
The above findings suggested that RNF38 destabilized SHP-1 protein by inducing its polyubiquitination. Since SHP-1 is a nontransmembrane protein tyrosine phosphatase, which serves as a negative regulator of STAT3 signaling [15] , we then evaluated whether RNF38 regulated STAT3 signaling in gastric cancer. As shown in Fig. 4A , the luciferase assay showed that overexpression of RNF38 increased STAT3-derived luciferase activity in a concentration-dependent manner. The immunoblotting assay also revealed that overexpression of RNF38 activated STAT3 by downregulating SHP-1 (Fig. 4B) . In contrast, knockdown of RNF38 significantly inhibited STAT3 activation by upregulating SHP-1 (Fig. 4C ). In addition, knockdown of RNF38 also significantly inhibited the transcription of STAT3 target genes, including Cyclin D1, Mcl1 and XIAP (Fig. 4D-F) . These results suggested that RNF38 regulated SHP-1/STAT3 signaling in gastric cancer cells. It is known that activation of STAT3 promotes cell growth in tumors [7, 16, 17] , then we evaluated whether RNF38-mediated cell growth of gastric cancer cells. As shown in Fig. 5A,B , overexpression or knockdown of RNF38 promoted or suppressed cell growth of gastric cancer in vitro. Further study in nude mice showed that knockdown of RNF38 delayed tumor growth of gastric cancer in vivo (Fig. 5C-F) . These indicated that RNF38 was functional in gastric cancer, and regulated cell growth by mediating SHP-1/STAT3 signaling.
Discussion
The ubiquitin-proteasome system (UPS) is an important signaling for regulating the degradation or function of intracellular proteins in many diseases, including tumors [18, 19] . The UPS is ATP-dependent and three classes of enzymes are required for mediating protein ubiquitination, including ubiquitin-activating enzyme E1, ubiquitinconjugating enzyme E2 and ubiquitin ligase E3 [20] [21] [22] . Among these, E3 ubiquitin ligases represent highly attractive protein targets for drug discovery, because the significance of E3 ligases as prospective targets for small molecule modulation is reinforced by ever growing evidences of their roles in tumors and other diseases [23, 24] .
As the major components of E3 ligases, RING finger proteins are involved in either the progression or suppression of tumorigenesis [25, 26] . In this study, RNF38 was found upregulated in gastric cancer and associated with poor prognosis of gastric cancer patients (Fig. 1) . Importantly, a recent study has also reported that RNF38 was upregulated in colorectal carcinoma, myeloma and prostate cancer according to the Oncomine database [3] . It has been also reported that elevated RNF38 was more frequent in nonsmall cell lung cancer (NSCLC) tissues than paired normal tissues, and elevated RNF38 was significantly associated with lymph node metastases, higher TNM stages, larger tumor size and predicted poor prognosis in NSCLC patients [3] . However, the prognostic role of RNF38 seems differed by different cancer type, for example, high RNF38 is favorable prognostic in renal cancer according to data from The Human Protein Atlas (via https://www.proteinatlas.org/) using TCGA samples for mRNA analysis.
The above statements suggested that RNF38 was an oncogenetic protein in many tumors. E3 ligases can transfer ubiquitin to substrates for their degradation in the ubiquitin-proteasome system, and are crucial for mediating the degradation of short-lived regulatory proteins including many oncogene products and tumor suppressors [27] [28] [29] . In this study, we found that RNF38 interacted with SHP-1 and induced its polyubiquitination for degradation, which suggested that RNF38 was a novel E3 ligase for SHP-1 ubiquitination (Figs 2 and 3) . Previous study also showed that SHP-1 could be ubiquitinated for degradation, and RNF6 was an E3 ligase for SHP-1 ubiquitination in colorectal cancer [8] . It is known that SHP-1 is a negative regulator of STAT3, and suppresses the cell growth of tumor cells [5, 6, 30] . In gastric cancer, SHP-1/STAT3 axis is important for gastric cancer tumorigenesis and can be as a target for drug discovery [17, 31] . Then, we evaluated whether RNF38 regulated cell growth of gastric cancer, and we found that overexpression or knockdown of RNF38 promoted or suppressed cell growth of gastric cancer cells, respectively, by regulating SHP-1/ STAT3 signaling (Figs 4 and 5 ).
In conclusion, our present study demonstrated that RNF38 is functional in gastric cancer and triggeres STAT3 signaling by decreasing the stability of SHP-1 protein. This study suggests that targeting RNF38/ SHP-1/STAT3 axis may be a potential strategy for gastric cancer therapy.
